Global mortality and readmission rates following COPD exacerbation-related hospitalisation: a meta-analysis of 65 945 individual patients.

Autor:	Waeijen-Smit K; Department of Research and Development, Ciro, Horn, the Netherlands.; Department of Respiratory Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Faculty of Health Medicine and Life Sciences, Maastricht University Medical Centre (MUMC+), Maastricht, the Netherlands., Crutsen M; Pulmonary Function and Exercise Testing Laboratory, MUMC+, Maastricht, the Netherlands., Keene S; Department of Research and Development, Ciro, Horn, the Netherlands.; Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.; Department of Clinical Pharmacy and Toxicology, MUMC+, Maastricht, the Netherlands., Miravitlles M; Pneumology Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca, Vall d'Hebron Barcelona Hospital Campus, Ciber de Enfermedades Respiratorias (CIBERES), Barcelona, Spain., Crisafulli E; Respiratory Medicine Unit, Department of Medicine, University of Verona, Verona, Italy., Torres A; Department of Pulmonology, Hospital Clinic of Barcelona and University of Barcelona. Institut d'Investigacions Biomèdiques August Pi i Sunyer, Institución Catalana de Investigación y Estudios Avanzados, CIBERES, Barcelona, Spain., Mueller C; Cardiovascular Research Institute Base, Department of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland., Schuetz P; Medical University Department, Kantonsspital Aarau, Aarau, Switzerland., Ringbæk TJ; Department of Respiratory Medicine, Copenhagen University Hospital-Hvidovre, Hvidovre, Denmark., Fabbian F; Department of Medical Sciences, Faculty of Medicine, Pharmacy and Prevention, University of Ferrara, University Hospital of Ferrara, Ferrara, Italy., Mekov E; Department of Occupational Diseases, Medical University Sofia, Sofia, Bulgaria., Harries TH; Department of Population Health Sciences, School of Life Course and Population Sciences, King's College London, London, UK., Lun CT; Department of Medicine and ICU, Alice Ho Miu Ling Nethersole Hospital, Hong Kong, Hong Kong., Ergan B; Dokuz Eylul University, Faculty of Medicine, Department of Pulmonary and Critical Care, Division of Critical Care, Izmir, Turkey., Esteban C; Respiratory Department, Hospital Galdakao, Galdakao, Spain.; Instituto BioCruces-Bizkaia, Barakaldo, Spain.; Red de Investigación en Servicios Sanitarios y Enfermedades Crónicas, Red de Investigación en Cronicidad, Atención Primaria y Promoción de la Salud, Bizkaia, Spain., Quintana Lopez JM; Red de Investigación en Servicios Sanitarios y Enfermedades Crónicas, Red de Investigación en Cronicidad, Atención Primaria y Promoción de la Salud, Bizkaia, Spain.; Unidad de Investigación, Hospital Galdakao-Usansolo, Galdakao, Spain., López-Campos JL; Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/Universidad de Sevilla, Seville, Spain.; CIBERES, Instituto de Salud Carlos III, Madrid, Spain., Chang CL; Department of Respiratory Medicine, Waikato Hospital, Hamilton, New Zealand., Hancox RJ; Department of Respiratory Medicine, Waikato Hospital, Hamilton, New Zealand.; Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand., Shafuddin E; Department of Respiratory Medicine, Waikato Hospital, Hamilton, New Zealand., Ellis H; Department of Respiratory Medicine, Waikato Hospital, Hamilton, New Zealand., Janson C; Department of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden., Suppli Ulrik C; Department of Respiratory Medicine, Copenhagen University Hospital-Hvidovre, Hvidovre, Denmark., Gudmundsson G; Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland.; Faculty of Medicine, University of Iceland School of Health Sciences, Reykjavik, Iceland., Epstein D; Critical Care Division, Rambam Health Care Campus, Haifa, Israel., Dominguez J; Servei de Microbiologia, Hospital Universitari Germans Trias i Pujol, Institut d'Investigació Germans Trias i Pujol, Universitat Autònoma de Barcelona, CIBERES, Barcelona, Spain., Lacoma A; Servei de Microbiologia, Hospital Universitari Germans Trias i Pujol, Institut d'Investigació Germans Trias i Pujol, Universitat Autònoma de Barcelona, CIBERES, Barcelona, Spain., Osadnik C; Department of Physiotherapy, Monash University, Clayton, Australia., Alia I; Intensive Care Units, Hospital Universitario de Getafe, CIBERES, Getafe, Spain., Spannella F; Internal Medicine and Geriatrics, Hypertension Excellence Centre of the European Society of Hypertension, IRCCS INRCA, Ancona, Italy.; Department of Clinical and Molecular Sciences, University Politecnica delle Marche, Ancona, Italy., Karakurt Z; Respiratory Critical Care Unit, University of Health Sciences Istanbul Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey., Mehravaran H; Pulmonary and Critical Care Division, Department of Internal Medicine, Mazandaran University of Medical Sciences, Sari, Iran., Utens C; Libra, Rehabilitation and Audiology, Eindhoven, the Netherlands., de Kruif MD; Department of Pulmonary Medicine, Zuyderland Medical Center, Heerlen, The Netherlands., Ko FWS; Department of Medicine and Therapeutics, Prince of Wales Hospital, Hong Kong, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong., Trethewey SP; Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, UK.; University of Exeter, Exeter, UK., Turner AM; Institute for Applied Health Research, University of Birmingham, Birmingham, UK.; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Bumbacea D; Department of Pneumology and Acute Respiratory Care, Elias Emergency University Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania., Murphy PB; Lane Fox Unit, Guy's and St Thomas' NHS Foundation Trust, London, UK.; Centre for Human and Applied Physiological Sciences, King's College, London, UK., Vermeersch K; Department of Chronic Diseases, Metabolism and Ageing, Research Group BREATHE, KU Leuven, Leuven, Belgium., Zilberman-Itskovich S; Nephrology Division, Assaf-Harofeh (Shamir) Medical Center, Be'er Ya'akov, Israel.; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel., Steer J; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.; Respiratory Department, North Tyneside General Hospital, North Shields, UK., Echevarria C; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.; Respiratory Department, Royal Victoria Infirmary, Newcastle upon Tyne, UK., Bourke SC; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.; Respiratory Department, North Tyneside General Hospital, North Shields, UK., Lane N; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.; Respiratory Department, Royal Victoria Infirmary, Newcastle upon Tyne, UK., de Batlle J; Group of Translational Research in Respiratory Medicine, Institut de Recerca Biomèdica de Lleida (Fundació Dr Pifarré), Lleida, Spain.; CIBERES, Madrid, Spain., Sprooten RTM; Department of Respiratory Medicine, MUMC+, Maastricht, The Netherlands., Russell R; School of Immunology and Microbial Sciences, Guy's Campus, Kings College, London, UK., Faverio P; School of Medicine and Surgery, University of Milan Bicocca, Respiratory Unit, San Gerardo Hospital, ASST Monza, Monza, Italy., Cross JL; Faculty of Medicine and Health, University of East Anglia, Norwich, UK., Prins HJ; Department of PMR, Libra, Rehabilitation and Audiology, Eindhoven, The Netherlands.; Department of PMR, Anna Hospital, Geldrop, The Netherlands.; Department of PMR, Catharina Hospital, Eindhoven, The Netherlands., Spruit MA; Department of Research and Development, Ciro, Horn, the Netherlands.; Department of Respiratory Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Faculty of Health Medicine and Life Sciences, Maastricht University Medical Centre (MUMC+), Maastricht, the Netherlands., Simons SO; Department of Respiratory Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Faculty of Health Medicine and Life Sciences, Maastricht University Medical Centre (MUMC+), Maastricht, the Netherlands., Houben-Wilke S; Department of Research and Development, Ciro, Horn, the Netherlands., Franssen FME; Department of Research and Development, Ciro, Horn, the Netherlands.; Department of Respiratory Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Faculty of Health Medicine and Life Sciences, Maastricht University Medical Centre (MUMC+), Maastricht, the Netherlands.
Jazyk:	angličtina
Zdroj:	ERJ open research [ERJ Open Res] 2024 Feb 26; Vol. 10 (1). Date of Electronic Publication: 2024 Feb 26 (Print Publication: 2024).
DOI:	10.1183/23120541.00838-2023
Abstrakt:	Background: Exacerbations of COPD (ECOPD) have a major impact on patients and healthcare systems across the world. Precise estimates of the global burden of ECOPD on mortality and hospital readmission are needed to inform policy makers and aid preventive strategies to mitigate this burden. The aims of the present study were to explore global in-hospital mortality, post-discharge mortality and hospital readmission rates after ECOPD-related hospitalisation using an individual patient data meta-analysis (IPDMA) design. Methods: A systematic review was performed identifying studies that reported in-hospital mortality, post-discharge mortality and hospital readmission rates following ECOPD-related hospitalisation. Data analyses were conducted using a one-stage random-effects meta-analysis model. This study was conducted and reported in accordance with the PRISMA-IPD statement. Results: Data of 65 945 individual patients with COPD were analysed. The pooled in-hospital mortality rate was 6.2%, pooled 30-, 90- and 365-day post-discharge mortality rates were 1.8%, 5.5% and 10.9%, respectively, and pooled 30-, 90- and 365-day hospital readmission rates were 7.1%, 12.6% and 32.1%, respectively, with noticeable variability between studies and countries. Strongest predictors of mortality and hospital readmission included noninvasive mechanical ventilation and a history of two or more ECOPD-related hospitalisations <12 months prior to the index event. Conclusions: This IPDMA stresses the poor outcomes and high heterogeneity of ECOPD-related hospitalisation across the world. Whilst global standardisation of the management and follow-up of ECOPD-related hospitalisation should be at the heart of future implementation research, policy makers should focus on reimbursing evidence-based therapies that decrease (recurrent) ECOPD. Competing Interests: Conflict of interest: K. Waeijen-Smit, M. Crutsen, S. Keene, T.J. Ringbæk, F. Fabbian, C-t. Lun, B. Ergan, C. Estebam, J.M. Quintana Lopez, C.L. Chang, R.J. Hancox, E. Shafuddin, H. Ellis, C. Janson, G. Gudmundsson, D. Epstein, A. Lacoma, C. Osadnik, I. Alia, F. Spannella, Z. Karakurt, H. Mehravaran, C. Utens, M.D. de Kruif, F.W.S. Ko, S.P. Trethewey, K. Vermeersch, S. Zilberman-Itskovich, C. Echevarria, R.T.M. Sprooten, P. Faverio, H.J. Prins and S. Houben-Wilke have no grants or personal fees to report. Conflict of interest: M. Miravitlles has received speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Menarini, Kamada, Takeda, Zambon, CSL Behring, Specialty Therapeutics, Janssen, Grifols and Novartis, consulting fees from AstraZeneca, Atriva Therapeutics, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, CSL Behring, Inhibrx, Ferrer, Menarini, Mereo Biopharma, Spin Therapeutics, ONO Pharma, Palobiofarma SL, Takeda, Novartis, Novo Nordisk, Sanofi and Grifols and research grants from Grifols. Conflict of interest: E. Crisafulli has received honoraria for lecturing, scientific advisory boards and participation in clinical studies for AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Menarini, Novartis, Qbgroup and Sanofi. Conflict of interest: A. Torres reports speaker/consulting honoraria from Pfizer, MSD, Janssen and Biomerieux. Conflict of interest: C. Mueller has received research support from the Swiss National Science Foundation, the Swiss Heart Foundation, the University of Basel, the University Hospital Basel, the KTI, Abbott, Beckman Coulter, BRAHMS, Idorsia, LSI-Medience, Ortho Diagnostics, Novartis, Roche, Siemens, SpinChip and Singulex, as well as speaker/consulting honoraria from Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, Idorsia, Novartis, Osler, Roche, SpinChip and Sanofi, all outside the submitted work. Conflict of interest: P. Schuetz has received grants from Nestle, Abbot, bioMerieux and Thermofisher outside the submitted work. Conflict of interest: E. Mekov has received grants and personal fees from Chiesi, and speaker or consulting fees from AstraZeneca and Chiesi. Conflict of interest: T.H. Harries is supported by a National Institute for Health and Care Research Academic Clinical Lectureship. Conflict of interest: J.L. López-Campos has received honoraria during the last 3 years for lecturing, scientific advice, participation in clinical studies or writing for publications for (alphabetical order): AstraZeneca, Bial, Boehringer, Chiesi, CSL Behring, Faes, Ferrer, Gebro, Grifols, GSK, Megalabs, Menarini and Novartis. Conflict of interest: C.S. Ulrik has received personal fees and grants from AstraZeneca, Chiesi, Boehringer Ingelheim, GSK, Novartis, Sanofi, Menarini, TEVA, ALK-Abello, Takeda, Orion Pharma, TFF Pharmaceuticals and Covis Pharma outside the submitted work. Conflict of interest: J. Dominguez has received honoraria for lectures from Oxford Immunotec (UK) and received payments for license transference from GenID (Germany), and grants from La Fundació La Marató TV3, Instituto de Salud Carlos III (CP03/00112), Catalan Pulmonology Society (SOCAP), Catalan Pulmonology Foundation (FUCAP) and Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). Conflict of interest: A.M. Turner reports research grants outside the submitted work from AstraZeneca, Resmed, Phillips, Chiesi, Grifols, CSL Behring and NIHR, and honoraria from GSK and Boehringer Ingelheim. Conflict of interest: D. Bumbacea has received grants and personal fees in the last 3 years from AstraZeneca, Eli Lilly, Novartis, Sanofi and Synairgen outside of the submitted work. Conflict of interest: PBM has received grants and personal fees from Philips, ResMed, Breas, Chiesi, Fischer & Paykel and, Sanofi outside the submitted work. Conflict of interest: J. Steer has received grants and honoraria, outside the submitted work, from Chiesi, Menarini Group, AstraZeneca and Pfizer. Conflict of interest: S.C. Bourke has received research grants from GSK (BEC COPD IRAS 285200), and additional support from Radiometer for an NIHR-funded study (NIVOW IRAS 313485), Philips, ResMed, and Pfizer Open Air, took part in clinical advisory boards with Philips and AstraZeneca, and has received honoraria from Boehringer Ingelheim, Chiesi, GSK, and AstraZeneca. Conflict of interest: N. Lane reports research grants from Bright Northumbria and The ResMed Foundation; and nonfinancial support from Chiesi and BREAS outside the submitted work. Conflict of interest: J. de Batlle acknowledges receiving financial support from Instituto de Salud Carlos III (Miguel Servet 2019: CP19/00108), co-funded by the European Social Fund, “Investing in your future”. Conflict of interest: R. Russell has received personal fees, outside of the submitted work, from AstraZeneca, Chiesi, Covis, GlaxoSmithKline and Boehringer Ingelheim. Conflict of interest: J.L. Cross has received grants from National Institute of Health Research. Conflict of interest: M.A. Spruit has received grants from the Netherlands Lung Foundation, Stichting Asthma Bestrijding, AstraZeneca, Boehringer Ingeheim, TEVA and CHIESI outside the submitted work. Conflict of interest: S.O. Simons has received grants and personal fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Chiesi outside the submitted work. Conflict of interest: F.M.E. Franssen has received grants and personal fees from AstraZeneca, Chiesi, Boehringer Ingelheim, Glaxosmithkline, Novartis and MSD outside the submitted work. Conflict of interest: All authors declare no conflicts of interest in relation to the present study. (Copyright ©The authors 2024.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu